IPP Bureau
Clariant Healthcare debuts in CPhI India
By IPP Bureau - December 20, 2023
Clariant Healthcare highlighted Vitipure Meglumine LEX and VitiPure Superior at the recently concluded CPhI India
KBR and HJF bags contract to aid military neuroscience research
By IPP Bureau - December 20, 2023
KBR will provide outreach, education and data analytics to support critical neuroscience research for the prevention and treatment of military members with CTE
Asahi Kasei opens new Bioprocess Technical Center in China
By IPP Bureau - December 20, 2023
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
Venus Remedies' R3SET forays into wellness
By IPP Bureau - December 20, 2023
The launch of R3SET Detox Candies positions the brand at the forefront of the wellness journey
Briefs: Aurobindo Pharma and Granules Pharmaceuticals
By IPP Bureau - December 20, 2023
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
AstraZeneca Pharma India to launch Enhertu in January 2024
By IPP Bureau - December 20, 2023
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Vijaya Diagnostic to acquire P H Diagnostic for Rs. 134.65 Cr
By IPP Bureau - December 20, 2023
Additionally, Rs. 12.85 crores shall be infused into the P H Diagnostic by way of either Equity or Loan to pay the existing debt
Biocon Academy conducts 8th Graduation Day
By IPP Bureau - December 19, 2023
Five batches across four programs of Biocon Academy participated in the graduation ceremony
CII recognized Cadila among Top 50 Innovative Companies in India
By IPP Bureau - December 19, 2023
Sanofi India appoints Himanshu Bakshi as GM - Consumer Healthcare Business
By IPP Bureau - December 19, 2023
His most recent stint was with Danone India as its Managing Director
Zydus receives USFDA approval USFDA to initiate Phase II clinical trial of ZYIL1 for Parkinson's disease
By IPP Bureau - December 18, 2023
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Lupin receives tentative USFDA approval for Sitagliptin Tablets
By IPP Bureau - December 18, 2023
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
Zydus receives final approval from the USFDA for Lacosamide Tablets
By IPP Bureau - December 18, 2023
Lacosamide is indicated to treat partial-onset seizures
Ami Organics inks agreement with Fermion for two additional APIs
By IPP Bureau - December 18, 2023
The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
Biocon Biologics concludes integration of acquired Biosimilars business in 120 countries
By IPP Bureau - December 18, 2023
10+ emerging markets, Japan & ANZ transition in final phase
